CrushSCI.com
104.2Average days
110.5Median days
5Fastest days
229Longest days
902025 publications

Paper Review Records

All Paper Review Records

12 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

110 days

Integrative genetic analyses for drug repurposing identify emodin as a candidate modulator of STAT3 signaling in abdominal aortic aneurysm

Authors
Yingjie Liu; Zhijun Xu; Lin Deng; Chi Zhang; Xiao Ruan; Linlu Zhao; Ying Yang; Zanxin Wang; Haocheng LuShow moreShow less
Affiliations
Department of Pharmacology, Joint Laboratory of Guangdong-Hong Kong Universities for Vascular Homeostasis and Diseases, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, 518055, China; School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510006, China; Department of Cardiology, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China; Engineering Research Center of Tropical Medicine Innovation and Transformation, Ministry of Education, College of Pharmacy, Hainan Medical University, Haikou, 571199, China; Division of Cardiovascular Surgery, Cardiac and Vascular Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, 518000, ChinaShow moreShow less
Source PDF DOI Publisher page
26 days

Characterization of an adjustable partial portal vein ligation model reveals flow-dependent intimal and medial remodeling of the extrahepatic portal vein

Authors
Tamasi Roy; Kristóf Nagy; Péter Horváth; András Kriston; Ferenc Kovács; Sudha Ananth; Gergely Huszty; Zsuzsanna Kolostyák; Attila Fintha; Gábor CsányiShow moreShow less
Affiliations
Vascular Biology Center, Medical College of Georgia, Augusta University, 1460 Laney Walker Blvd., Augusta, GA 30912, USA; Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary; Synthetic and Systems Biology Unit, HUN-REN Biological Research Centre, Szeged, Hungary; Department of Surgery, Transplantation and Gastroenterology, Semmelweis University, Budapest, Hungary; Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, 1460 Laney Walker Blvd., Augusta, GA, 30912, USAShow moreShow less
Source PDF DOI Publisher page
111 days

TUG-891-mediated FFAR4 activation attenuates vascular remodeling via suppression of aberrant browning and lipolysis in perivascular adipose tissue

Authors
Ai Jiang; Tianjiao Wang; Xiaobing Xu; Zhang Chen; Yujuan Li; Jiahe Du; Yixuan Jiang; Xinzhi LiShow moreShow less
Affiliations
School of Pharmacy, Faculty of Chinese Medicine & Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Taipa, Macao, China; State Key Laboratory of Mechanism and Quality of Chinese Medicine, Macau University of Science and Technology, Taipa, Macao, ChinaShow moreShow less
Source PDF DOI Publisher page
45 days

Aquaporin-1 facilitates the transport of hydrogen peroxide and nitric oxide during endothelium-dependent vasorelaxation

Authors
Omar Echeverría Rodríguez; Sebastián Ramírez Rodríguez; Sara Daniela Hernández Torres; Héctor Riveros Rosas; Itzell A. Gallardo Ortíz; Rafael Villalobos Molina; María Magdalena Vilchis LanderosShow moreShow less
Affiliations
Department of Biochemistry, Faculty of Medicine, Universidad Nacional Autónoma de México, Coyoacán, 04510 Mexico City, Mexico; Division of Research and Postgraduate Studies, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, 54090, State of Mexico, MexicoShow moreShow less
Source PDF DOI Publisher page
51 days

Pan-peroxisome proliferator-activated receptor agonist IVA337 alleviates secondary lymphedema via inhibiting TGFβ/SMAD2/3 signaling pathway

Authors
Jingjing Pang; Long Nguyen Hoang Do; Esteban Delgado; Jianan Zhao; Liam Flynn; Hongxia Liu; Michael Autieri; Xiaofeng Yang; Xiaolei LiuShow moreShow less
Affiliations
Lemole Center for Integrated Lymphatics and Vascular Research, United States of AmericaShow moreShow less
Source PDF DOI Publisher page
157 days

Multi-omics and experimental validation reveal the proliferative mechanism of ACSL4 in pulmonary hypertension and identify potential FDA-approved drugs via in silico screening

Authors
Wei Chen; Yiting Dong; Qihao Shi; Hongbing Meng; Jiawei Sun; Congmei Han; Chenjie Yan; Chendong Wu; Jing Wang; Adriana Georgescu; Keke Jin; Linbo YuanShow moreShow less
Affiliations
Wenzhou Medical University, Wenzhou, China; Renji College, Wenzhou Medical University, Wenzhou 325000, China; Xinjiang General Station of Exit and Entry Frontier Insp, Xinjiang, China; Department of Pathophysiology, School of Basic Medical Science, Wenzhou Medical University, Wenzhou, China; Department of Physiology, School of Basic Medical Science, Wenzhou Medical University, Wenzhou, China; Department of Pathophysiology and Cellular Pharmacology, Institute of Cellular Biology and Pathology ‘Nicolae Simionescu’ of Romanian Academy, Bucharest, RomaniaShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does VASCULAR PHARMACOLOGY take to review a manuscript?

As of 2026-11-19, CrushSCI has 12 complete review records for VASCULAR PHARMACOLOGY. The fastest paper went from submission to acceptance in 5 days (Formoterol fumarate attenuates atherosclerosis and improves cardiometabolic dysfunction in ApoE-deficient mice, received 2026-08-09, accepted 2026-08-14); the slowest took 229 days. The average is 104.2 days and the median is 110.5 days. The fastest record has an unusually short interval; please check the original source.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.